deal expand breast health portfolio
report revenu yoy constant
currenc cc ahead our/street upsid driven strength
diagnost tuck-in deal better surgic perform higher legaci blood
screen organ basi ex blood sale increas yoy ad
gm declin yoy estimate due fx
headwind tariff mix higher servic cost opm increas yoy
vs street visibl alpha ep vs our/street grew yoy
guid rais tuck-in ssi deal boost
rais guid yoy cc revenu growth vs
prior faxitron focal contribut quarter vs
expect impli yoy pro forma organ revenu growth
ep guid narrow
see sale vs our/street increment fx
headwind ep vs our/street ou growth
neg impact latam mostli breast health final cynosur stabil
improv qoq june announc agreement acquir
superson imagin ssi french ultrasound medic imag provid
complement breast health portfolio sale expect
ssi doubl digit grower updat model includ ssi upon
deal close expect provid boost overal
good quarter core growth molecular diagnost mdx core
growth breast imag note share run print
street like anticip solid quarter
adjust est reiter neutral rate rais po
rais sale ep estimate
rais po base ep estimate higher due
peer group expans ahead three-year histor averag given
recent growth improv reiter neutral rate given slower organ breast
health growth run-up print
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
lead manufactur medic
devic product focus heathcar need
mammographi breast biopsi earli stage
treatment remov uterin fibroid
compani acquir cynosur lead
medic aesthet compani larg portfolio
laser-bas product
core mammographi diagnost
busi deliv solid perform
especi ou market help
partial off-set issu relat
cynosur busi acquir continu
reserv cynosur
lack visibl concern although
po base approxim calendar ep estim impli
ev/ebitda ahead three-year histor averag
compani diagnost med-tech peer multipl believ
justifi given strength breast molecular diagnost
upsid risk po faster growth core diagnost mammographi
gynecolog surgeri end market improv cynosur
synergi addit tuck-in deal
downsid risk po cynosur competit pressur slower uptak
reimburs new product unfavor chang clinic practic guidelin
manag departur regulatori risk faster declin legaci busi
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us life scienc diagnost tool anim health coverag cluster
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
